Our laboratory focuses on the study of molecular pathways that regulate brain tumor growth. Our long-term goal is to develop therapeutic paradigms that target specific properties of primary brain tumors, including genetic alterations in cancer signaling pathways, unique aspects of brain tumor metabolism, or interactions of brain tumor cells with their brain microenvironment. Our studies in experimental brain tumor models are closely linked to the evaluation of novel agents in early-phase clinical trials.
Ingo K. Mellinghoff, MD, FACP
Research FocusPhysician-scientist Ingo Mellinghoff studies signal transduction alterations in primary brain tumors.
EducationMD, Technical University Munich (Germany)
- Miller A.M. et al. (2019). Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019 Jan 23. doi: 10.1038/s41586-019-0882-3.
- Rohle D et al., (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340 (6132): 626-30.
- Member, Association of American Physicians (2020)
- Member, American Society of Clinical Investigation (2013)
- Advanced Clinical Research Award, American Society of Clinical Oncology (2009)
- Clinical Scientist Development Award, Doris Duke Charitable Foundation (2008)
- Translational Science Award, Sidney Kimmel Foundation (2008)
- Distinguished Scientist, Sontag Foundation (2007)
- Scholar, Forbeck Research Foundation (2005)
- Young Investigator Award, American Society of Clinical Oncology (2003)